<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215149</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI B003/ IPCAVD-004</org_study_id>
    <nct_id>NCT01215149</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults</brief_title>
  <official_title>A Phase 1 Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Safety and Immunogenicity of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HIV Vaccine Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ragon Institute of MGH, MIT and Harvard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of Ad26.ENVA.01 and&#xD;
      Ad35-ENV in low-risk for HIV-uninfected healthy adults administered in heterologous and&#xD;
      homologous prime-boost regimens at different time intervals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double-blind placebo-controlled trial assessing the order of&#xD;
      vector priming and boosting (Ad26 versus Ad35), the timing of boost (3 versus 6 months) and&#xD;
      the homologous versus heterologous regimen at the 3-month time interval. Groups A-D will be&#xD;
      enrolled in Boston, MA, USA, Groups E-H will be enrolled at the East African Clinical&#xD;
      Research Centres and Groups I-L will be enrolled at the South African Clinical Research&#xD;
      Centres.&#xD;
&#xD;
      Volunteers will be screened up to 56 days before vaccination and will be followed for 12&#xD;
      months after the second vaccination.&#xD;
&#xD;
      Approximately 212 volunteers will be randomized to receive either vaccine or placebo within a&#xD;
      group (A-L); Groups A-D, Groups E-H and Groups I-L will be randomized separately. Up to 7%&#xD;
      over-enrolment (approximately 15 volunteers) will be allowed to facilitate enrolment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>15-18 months approximately</time_frame>
    <description>To evaluate the safety and tolerability of Ad26.ENVA.01 and Ad35-ENV administered in heterologous and homologous prime-boost regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the immunogenicity of Ad26.ENVA.01 and Ad35-ENV administered in heterologous prime-boost regimens at 3 versus 6 month intervals&#xD;
To evaluate the immunogenicity of Ad26.ENVA.01 and Ad35-ENV administered in heterologous and homologous prime-boost regimens at 3 month interval&#xD;
To evaluate anti-vector immunity induced by Ad26.ENVA.01 and Ad35-ENV administered in heterologous and homologous prime-boost regimens</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 6. Vaccine:Placebo=10:3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENVA at Month 0 followed by Ad26.ENVA.01 at Month 6. Vaccine:Placebo=10:3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=10:3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=10:3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad35-ENV vaccine</intervention_name>
    <description>Recombinant adenovirus serotype 35 vector vaccine 5x10^10 vp, delivered IM</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.ENVA.01 vaccine</intervention_name>
    <description>Recombinant adenovirus serotype 26 vector vaccine, 5x10^10 vp delivered IM</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Control</intervention_name>
    <description>Colorless 10mm Tris/HCl buffer</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group J</arm_group_label>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_label>Group L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female, as assessed by a medical history, physical exam, and&#xD;
             laboratory tests;&#xD;
&#xD;
          -  At least 18 years of age on the day of screening and has not reached his/her 51st&#xD;
             birthday on the day of first vaccination;&#xD;
&#xD;
          -  Willing to comply with the requirements of the protocol and available for follow-up&#xD;
             for the planned duration of the study;&#xD;
&#xD;
          -  In the opinion of the Principal Investigator or designee, and based on Assessment of&#xD;
             Informed Consent Understanding (AOU) results, has understood the information provided&#xD;
             and potential risks linked to vaccination and participation in the trial; written&#xD;
             informed consent will be provided by the volunteer before any study-related procedures&#xD;
             are performed;&#xD;
&#xD;
          -  Willing to undergo HIV testing, risk reduction counselling, receive HIV test results&#xD;
             and committed to maintaining low risk behaviour for the trial duration as defined by&#xD;
             the protocol;&#xD;
&#xD;
          -  If a female of childbearing potential, willing to use an effective non-barrier method&#xD;
             of contraception (oral or injectable hormonal contraceptive; intrauterine device&#xD;
             [IUD]) from screening until at least 4 months after the last study vaccination;&#xD;
&#xD;
          -  Assessed by the clinic staff as being at &quot;low risk&quot; for HIV infection on the basis of&#xD;
             sexual behaviours within the 12 months prior to enrolment;&#xD;
&#xD;
          -  All female volunteers must be willing to undergo pregnancy tests at time points&#xD;
             indicated in the protocol and must test negative prior to each study vaccination;&#xD;
&#xD;
          -  All sexually active males (unless anatomically sterile) must be willing to use an&#xD;
             effective method of contraception (such as consistent condom use) from the day of&#xD;
             first vaccination until at least 4 months after the last vaccination;&#xD;
&#xD;
          -  Willing to forgo donations of blood or any other tissues during the study and, for&#xD;
             those who test HIV positive due to trial vaccination (vaccine-induced HIV&#xD;
             seropositivity), until the anti-HIV antibody titers become undetectable.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Confirmed HIV-1 or HIV-2 infection;&#xD;
&#xD;
          -  Any clinically relevant abnormality on history or examination including history of&#xD;
             immunodeficiency or autoimmune disease; use of systemic corticosteroids (the use of&#xD;
             topical or inhaled steroids is permitted); immunosuppressive, anticancer,&#xD;
             antituberculosis or other medications considered significant by the investigator&#xD;
             within the previous 6 months;&#xD;
&#xD;
          -  Any clinically significant acute or chronic medical condition that is considered&#xD;
             progressive, or in the opinion of the investigator, makes the volunteer unsuitable for&#xD;
             participation in the study;&#xD;
&#xD;
          -  Reported risky behaviour for HIV infection within 12 months prior to vaccination, as&#xD;
             defined by the protocol&#xD;
&#xD;
          -  If female, pregnant or planning a pregnancy within 4 months after last vaccination; or&#xD;
             lactating;&#xD;
&#xD;
          -  Asthma requiring high-dose oral or inhaled corticosteroids;&#xD;
&#xD;
          -  Fever &gt; 100.4° F/38.0° C within 72 hours prior to vaccine administration;&#xD;
&#xD;
          -  Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency,&#xD;
             coagulopathy or platelet disorder that requires special precautions) (Note: A&#xD;
             volunteer who states that he or she has easy bruising or bleeding, but does not have a&#xD;
             formal diagnosis and has IM injections and blood draws without any adverse experience&#xD;
             is eligible);&#xD;
&#xD;
          -  History of splenectomy;&#xD;
&#xD;
          -  Any abnormal laboratory parameters as defined by the protocol;&#xD;
&#xD;
          -  Receipt of live-attenuated vaccine within the previous 60 days or planned receipt&#xD;
             within 60 days after vaccination with Investigational Product (within 14 days for live&#xD;
             attenuated influenza vaccine [LAIV]); or receipt of other vaccine (e.g., influenza,&#xD;
             pneumococcal), allergy treatment with antigen injections or tuberculin skin test&#xD;
             within the previous 14 days or planned receipt within 14 days after vaccination with&#xD;
             Investigational Product;&#xD;
&#xD;
          -  Receipt of blood transfusion or blood-derived products within the previous 3 months;&#xD;
&#xD;
          -  Participation in another clinical trial of an Investigational Product currently,&#xD;
             within the previous 3 months or expected participation during this study;&#xD;
&#xD;
          -  Receipt of another investigational HIV vaccine candidate (Note: receipt of an HIV&#xD;
             vaccine control or placebo will not exclude a volunteer from participation if&#xD;
             documentation is available and the Medical Monitor gives approval);&#xD;
&#xD;
          -  History of severe local or systemic reactogenicity to vaccines (e.g., anaphylaxis,&#xD;
             respiratory difficulty, angioedema);&#xD;
&#xD;
          -  Confirmed diagnosis of active hepatitis B, hepatitis C or active syphilis;&#xD;
&#xD;
          -  Seizure disorder: A participant who has had a seizure in the last 3 years is excluded.&#xD;
             (Not excluded: a participant with a history of seizures who has neither required&#xD;
             medications nor had a seizure for 3 years.);&#xD;
&#xD;
          -  Psychiatric condition that precludes compliance with the protocol. Specifically&#xD;
             excluded are persons with psychoses within the past 3 years, ongoing risk for suicide,&#xD;
             or history of suicide attempt or gesture within the past 3 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Baden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, Boston, MA, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaudensia Mutua, MB ChB, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya AIDS Vaccine Initiative, Kangemi, Kenya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Etienne Karita, MD, M.Sc., MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Projet San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda-Gail Bekker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Desmond Tutu HIV Foundation-Emavundleni Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Glenda Gray, MBBCH, FCPaeds(SA)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Perinatal HIV Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liesl Page-Shipp</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurum Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenya AIDS Vaccine Initiative</name>
      <address>
        <city>Kangemi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Projet San Francisco</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation-Emavundleni Research Centre</name>
      <address>
        <city>Cape Town (Nyanga)</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurum Institute</name>
      <address>
        <city>Klerksdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Rwanda</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.iavi.org</url>
    <description>International AIDS Vaccine Initiative</description>
  </link>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

